Search
Tebapivat
go.drugbank.com/drugs/DB19338InvestigationalTebapivat is under investigation in clinical trial NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-risk Myelodysplastic Syndromes (LR-MDS)).
MB-102 CD123 CAR
go.drugbank.com/drugs/DB17366InvestigationalMB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.
N-(2-Aminoethyl)-1-aziridineethanamine
go.drugbank.com/drugs/DB15643ExperimentalFirst described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236
Tarloxotinib
go.drugbank.com/drugs/DB14944InvestigationalTarloxotinib is under investigation in clinical trial NCT03743350 (NSCLC Exon 20 or HER2-activating Mutations).
Modakafusp alfa
go.drugbank.com/drugs/DB16399Investigationalinvestigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM
PR1 leukemia peptide vaccine
go.drugbank.com/drugs/DB15276InvestigationalPR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).
Unasnemab
go.drugbank.com/drugs/DB18837InvestigationalUnasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury).
Ingenol disoxate
go.drugbank.com/drugs/DB15109InvestigationalIngenol disoxate is under investigation in clinical trial NCT02120456 (Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk
Contusugene ladenovec
go.drugbank.com/drugs/DB05322InvestigationalINGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials.
Categories: Complex Mixtures